- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 02.10. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::STOCK EXCHANGE DISCLOSURE BY BIOCON LIMITED | 5 | SGX Company Announcements | ||
| 01.10. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 5 | SGX Company Announcements | ||
| 18.09. | Biocon Biologics' Yesafili (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases | 2 | CNW | ||
| 17.09. | Biocon Biologics Says FDA Approves Bosaya And Aukelso As Denosumab Biosimilars | 2 | RTTNews | ||
| 17.09. | Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya and Aukelso, Denosumab Biosimilars | 937 | PR Newswire | BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary... ► Artikel lesen | |
| 17.09. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 04.09. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | - | SGX Company Announcements | ||
| 07.08. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 23.07. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 23.07. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | - | SGX Company Announcements | ||
| 15.07. | Biocon Biologics Ltd: Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States | 93 | GlobeNewswire (Europe) | BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon... ► Artikel lesen | |
| 15.07. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 11.07. | EC approves Biocon Biologics' denosumab biosimilars Vevzuo and Evfraxy | 1 | PMLiVE | ||
| 07.07. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | - | SGX Company Announcements | ||
| 03.07. | Fortschritt für die Knochengesundheit: Europäische Kommission erteilt Zulassung für Denosumab-Biosimilars von Biocon Biologics | 302 | news aktuell | Bengaluru, Indien (ots/PRNewswire) - Biocon Biologics Ltd. (BBL), ein vollständig integriertes globales Biosimilar-Unternehmen und Tochtergesellschaft von Biocon Ltd., gab heute bekannt, dass die Europäische... ► Artikel lesen | |
| 03.07. | Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars | 369 | PR Newswire | BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission... ► Artikel lesen | |
| 03.07. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 30.06. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 27.06. | Biocon Biologics Ltd: Biocon Biologics Receives Health Canada Approval for Yesafili (aflibercept); First Global Launch Scheduled for July 2025 | 870 | GlobeNewswire (Europe) | TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd.... ► Artikel lesen | |
| 27.06. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| BIONTECH | 87,95 | +0,11 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
| BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics files $400M mixed securities shelf | ||
| COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten |
Das Unternehmen BIOCON BIOLOGICS GLOBAL PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 97,49 Euro und damit -0,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.